Skip to main content
OpenTrials
Completed

NCT Number: NCT00235001

Russian Study of the Efficacy and Safety of Tarka in Patients With Hypertension

This study will investigate antihypertensive activity and safety profile of Tarka in Russian hypertension patients by ambulatory blood pressure measurement (ABPM)

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hypertension Cardiovascular Diseases Vascular Diseases

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Global Medical Information-Abbott

North Chicago, Illinois, 60064, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Hypertension

Exclusion criteria

  • SBP > 180 mm Hg, DBP > 114 mm Hg
  • Subject has a hypersensitivity to trandolapril or verapamil

Treatment and study plan

trandolapril/verapamil

Drug

180/2 mg QD

Other names: ABT-TARKA, Tarka

Primary outcomes

  1. Change in blood pressure from baseline/blood pressure control

    Time frame: Baseline to 3 months of Tx

Secondary outcomes

  1. Absolute BP reduction from baseline, safety

    Time frame: Baseline to 3 months of Tx

Sponsors and collaborators

Lead sponsor

Abbott

Industry

Registry information

Official study title

A Multicenter, Open, Phase IV, 24-Hour Ambulatory Blood Pressure Monitoring Study of the Efficacy and Safety of Tarka in Patients With Arterial Hypertension

Important dates

Study start
2004
Primary completion
2006
First posted
Oct 10, 2005
Registry last updated
Jul 10, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.